Immuno-Oncology and Technology: Volume 13 to Volume 16

Title: Immuno-Oncology and Technology (IOTECH): Advancing the Frontiers of Immuno-Oncology Research

Introduction: IOTECH, the latest addition to the European Society for Medical Oncology’s esteemed journal portfolio, stands as a sister journal to Annals of Oncology and ESMO Open. With a commitment to publishing high-quality original research articles, reviews, perspectives, technology explained papers, letters to the editor, and editorials, IOTECH serves as a leading forum for the foremost experts in the field of Immuno-Oncology.

Scope and Aims: As a quarterly publication led by Editor in Chief, Professor John Haanen, and an international team of expert Editors and Editorial Board members, IOTECH encompasses pre-clinical and clinical studies exploring natural and therapy-induced innate and adaptive immune responses against both solid and haematological cancers. The journal’s primary focus lies in advancing the understanding of Immuno-Oncology and its technological applications to enhance clinical outcomes.

Key Areas of Coverage: IOTECH delves into various aspects of Immuno-Oncology, including the latest developments in immune responses against cancer. The journal features groundbreaking research on the immune system’s innate and adaptive responses to malignancies. By providing a platform for clinical studies, IOTECH seeks to facilitate the translation of Immuno-Oncology research into tangible patient benefits.

Emphasis on Technological Advancements: One of IOTECH’s distinguishing features is its strong emphasis on technological advancements in Immuno-Oncology. The journal highlights cutting-edge developments that unlock the potential of immune-based therapies. By deciphering and improving clinical outcomes through technological breakthroughs, IOTECH contributes significantly to the field’s progress.

Editorial Leadership: Under the guidance of esteemed Editor in Chief, Professor John Haanen, and a team of expert Editors and Editorial Board members, IOTECH maintains its commitment to rigorous peer review and the publication of high-quality content. By aligning with the values of the European Society for Medical Oncology, the journal upholds the highest standards of scientific integrity and ethical conduct.

Conclusion: IOTECH, as a sister journal to Annals of Oncology and ESMO Open, extends the European Society for Medical Oncology’s influence in the realm of Immuno-Oncology research. By disseminating original research, reviews, and technology explained papers, IOTECH fosters collaboration and innovation among leading experts in the field. As a distinguished platform for Immuno-Oncology research, IOTECH drives advancements in cancer treatment and stands as an invaluable resource for the global oncology community.

Volume 13: March 2022

Volume 14: June 2022

Volume 15: September 2022

Volume 16, Supplement 1, December 2022

Volume 16: December 2022